These are not FDA-approved for human consumption
It is not intended for human consumption, veterinary use, diagnostic purposes, or therapeutic applications
This study suggested VPA treatment as a potential antidote for PD prevention (Hsu et al., 2020)
Although a large number of short-term and medium-term clinical studies support the safety and efficacy of GLP-1RAs, there are insufficient data on the presence of delayed side effects with their long-term (decades) use (Guirguis et al., 2024)
Gala describes two current options: a standard GLP-1/GIP track advertised from $179/month on a 3-month plan, and a microdosing GLP-1/GIP track advertised from $149/month on a 3-month plan
For compounded options, the prescription goes to Aequita Pharmacy